November 2, 2020

Whom It May Concern
Company:
Representative:

KYORIN Holdings, Inc.
Yutaka Ogihara
Representative Director, President(Security Code: 4569, TSE 1st Sec.)Contact:
Telephone:

Yoshinori Tanifuji
Director, Corporate Planning03-3525-4707

Revision of Consolidated Financial Forecasts
TOKYO, Japan (November 2, 2020) ―KYORIN Holdings, Inc., today announced that it has madethe following revisions to its consolidated earnings forecasts for the first half of fiscal year ending
March 31, 2021. The earnings forecasts were previously announced on May 12, 2020.
1. The Revision of Consolidated Financial Forecasts for the first half of fiscal year ending March 31, 2021
(April 1, 2020 to September 30, 2020)(Unit: Millions of yen)

Net sales

OperatingincomeOrdinary
incomeNet income

Basicearnings
per share(yen)

Original forecast (A)52,800

2,400

2,600

1,900

33.17

Revised forecast (B)47,700

1,500

1,800

2,100

36.98

Change (B-A)－5,100

－900

－800

+200

―

Change (%)

－9.7

－37.5

－30.8

+10.5

―

48,299783

1,076834

14.56(for reference) Resultsof the previous period

2. Reason for revision of financial results forecast
Changes in the business environment during the first half of the current fiscal year include the spreadof COVID-19, the slump in the medical drug market due to patient’s suppressive behavior to go to
medical institution, and the delay in market penetration of new drug groups due to voluntary restriction
on MR activities. As a result, sales of new ethical drugs, etc. (Japan) are expected to be lower thaninitially expected, and sales are revised downward.
In terms of profits, gross profit is expected to decrease as sales decrease. On the other hand, SG&Aexpenses (excluding R & D expenses) are expected to be lower than initially projected due to the effectsof activity restrictions attributable to the spread of COVID-19, but the decrease in gross profit caused by
the decrease in sales could not be absorbed. Operating income and ordinary income are revised
downward.
As a debt exemption gain of approximately 1 billion yen will be recorded as extraordinary income,Quarterly net income attributable to owners of the parent company is revised upward. . It is a partial
exemption of repayment obligations for long-term debt borrowed from the National Research andDevelopment Agency Japan Science and Technology Agency.

3. Other
The full year consolidated financial results forecast for the fiscal year ending March 31, 2021 is now
being reviewed, will be disclosed it at the time of announcement of the results for the six months ended
September 30, 2020 (scheduled for November 5).

Supplementary material
1. About Sales
unit : ¥ billion

Sep/2019(A)Sales

New ethical drugs, etc.
（Japan）
New ethical drugs（Overseas）
Generic drugs

Sep/2020(B)Sep/2020(C)(original forecast)(revised forecast)

ChangeChange(C)－(A)(C)－(B)

48.3

52.8

47.7

－0.6

－5.1

33.7

36.8

32.8

－0.9

－4.0

0.4

0.3

0.5＋0.1

＋0.2

14.2

15.6

14.3

＋0.1

－1.3

2. About Main Product Sales
unit : ¥ billion

Sep/2019(A)New
ethical(Japan)

Sep/2020(B)Sep/2020(C)(original forecast)(revised forecast)

ChangeChange(C)－(A)(C)－(B)drugs,etc.

Flutiform

6.7

7.0

6.3

－0.4

－0.7

Desalex0

3.1

1.8＋1.8－1.3

Beova(KYORIN)

0.6

3.5

3.7＋3.1＋0.2

Lasvic tablets－

1.4

0.2

＋0.2

－1.2

Pentasa

6.8

5.9

6.3

－0.5

＋0.4

Uritos(KYORIN)

3.0

1.8

1.5

－1.5

－0.3

Nasonex

2.7

0.6

0.6

－2.1

±0Kipres(for adult)

2.4

1.8

1.7

－0.7

－0.1

Kipres(for children)

3.0

2.2

1.8

－1.2

－0.4

Mucodyne

2.8

2.2

1.4

－1.4

－0.8

Milton

1.1

1.1

1.1

±0±0

5.4

4.7

4.5

－0.9

－0.2

0.4

0.9

0.9

＋0.5

±0－

0.4

0.3

＋0.3

－0.1

Generic drugs
MONTELUKAST Tablets“KM”※1
Mometasone Nasal 50 ㎍“KYORIN”※2Imidafenacin
tablets &OD “KYORIN” ※3※1 Authorized generic drug for Kipres※2 Authorized generic drug for Nasonex※3Authorized generic drug for Uritos(Note) The above forecasts are based on information that is currently available and actual results may differ materiallyfrom those in the forecasts.